1-20 of 163
Arnon P. Kater
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

In-Depth Immune and Metabolic Profiling of GAIA/CLL13 Patients to Uncover Treatment-Specific Changes to the T-Cell Compartment

Chaja Feige Jacobs, Yannick D'Hargues, Sandra Robrecht, Moritz Fürstenau, Kirsten Fischer, Anna Maria Fink, Stephan Stilgenbauer, Christof Schneider, Eugen Tausch, Carsten Utoft Niemann, Caspar da Cunha-Bang, Julie Dubois, Ellen Van Der Spek, Andre Vlot, Yorick Sandberg, Mark-David Levin, Michael Hallek, Barbara F. Eichhorst, Arnon P. Kater, Fleur S. Peters
Journal: Blood
Blood (2024) 144 (Supplement 1): 1846.
https://doi.org/10.1182/blood-2024-209692
Published: 2024
Journal Articles

Informative Censoring in Randomized First-Line Trials of Chronic Lymphocytic Leukemia

Florian Simon, Rudy Ligtvoet, Moritz Fürstenau, Petra Langerbeins, Anna Maria Fink, Julia Von Tresckow, Paula Cramer, Christian Bjørn Poulsen, Thomas Illmer, Lothar Müller, Ursula Vehling-Kaiser, Michael J. Eckart, Liliya Sivcheva, Javier Loscertales, Kathleen Jentsch-Ullrich, Holger F. Hebart, Mark-David Levin, Caspar Da Cunha-Bang, Nadine Kutsch, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Sandra Robrecht, Arnon P. Kater, Carsten Utoft Niemann, Kirsten Fischer, Michael Hallek, Barbara F. Eichhorst, Othman Al-Sawaf
Journal: Blood
Blood (2024) 144 (Supplement 1): 6799.
https://doi.org/10.1182/blood-2024-203673
Published: 2024
Journal Articles

Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study

Billy Jebaraj, Eugen Tausch, Deyan Y. Yosifov, Christof Schneider, Moritz Fürstenau, Can Zhang, Sandra Robrecht, Caspar da Cunha-Bang, Mark-David Levin, Philipp Bernhard Staber, Tamar Tadmor, Patrick Thornton, Michael Gregor, Anna Maria Fink, Kirsten Fischer, Matthias Ritgen, Michael Hallek, Arnon P. Kater, Carsten Utoft Niemann, Barbara F. Eichhorst, Stephan Stilgenbauer
Journal: Blood
Blood (2024) 144 (Supplement 1): 4626.
https://doi.org/10.1182/blood-2024-204852
Published: 2024
Journal Articles

CELESTIAL-TNCLL: An Ongoing, Open-Label, Multiregional, Phase 3 Study of Sonrotoclax (BGB-11417) + Zanubrutinib vs Venetoclax + Obinutuzumab for Treatment-Naive CLL

Piers E.M. Patten, Arnon P. Kater, Jennifer A. Woyach, Jianyong Li, Talha Munir, Tommi Salmi, Patrick Phuong, Tian Tian, Mazyar Shadman
Journal: Blood
Blood (2024) 144 (Supplement 1): 3257.1.
https://doi.org/10.1182/blood-2024-198737
Published: 2024
Journal Articles

Improved Efficacy with Response- and MRD-Guided Ibrutinib-Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/Next STEP Phase 2 Trial

Mark-David Levin, Sabina Kersting, Julie Dubois, Bronno van der Holt, Caspar da Cunha-Bang, Doreen te Raa, Cecile Idink, Fransien De Boer, Jolanda Droogendijk, Koen de Heer, Leonie van der Burg, Marten R. Nijziel, Lidwine Tick, Henriettte Levenga, Matthijs Silbermann, Inge Ludwig, Aart Beeker, Mar Bellido, Anne-Marie Van Der Kevie-Kersemaekers, Clemens Mellink, Ine Meulendijks, Sjoerd Zoun-van den Dool, Martine Abrahamse-Testroote, Gerben Zwezerijnen, Carsten Utoft Niemann, Arnon P. Kater
Journal: Blood
Blood (2024) 144 (Supplement 1): 1013.
https://doi.org/10.1182/blood-2024-207452
Published: 2024
Journal Articles

First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis

Carsten Utoft Niemann, Talha Munir, Carolyn Owen, George Follows, Jose-Angel Hernandez Rivas, Ohad Benjamini, Ann Janssens, Mark-David Levin, Tadeusz Robak, Martin Simkovic, Sergey Voloshin, Vladimir I. Vorobyev, Loic Ysebaert, Natasha Schuier, Kurt Baeten, Ping Xu, Nguyet Tran, Bennett S. Levitan, Claire Kavanagh, Arnon P. Kater
Journal: Blood
Blood (2024) 144 (Supplement 1): 1871.
https://doi.org/10.1182/blood-2024-203269
Published: 2024
Journal Articles

Mutations in BCOR , CCND2 , NRAS and XPO1 Predict Clinical Outcomes upon MRD-Guided Venetoclax Plus Ibrutinib in Relapsed and Refractory Chronic Lymphocytic Leukemia

Christian Brieghel, Julie Dubois, Ida Kappel Buhl, Kazem Nasserinejad, Dennis De Rooij, Karl Nyrén, Hoa T Tran, Sabina Kersting, Mattias Mattsson, Juha Ranti, Rogier Mous, Gerrit Jan Veldhuis, Caspar da Cunha-Bang, Mark-David Levin, Valtteri Wirta, Richard Rosenquist, Arnon P. Kater, Carsten Utoft Niemann
Journal: Blood
Blood (2024) 144 (Supplement 1): 586.
https://doi.org/10.1182/blood-2024-204532
Published: 2024
Journal Articles

Quality of Life in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Improves after Minimal Residual Disease-Guided Treatment with Ibrutinib Plus Venetoclax

Laura Elisabeth Maria Eurelings, Emelie Curovic Rotbain, Sabina Kersting, Lina Van Der Straten, Lisbeth Enggaard, Gerrit Jan Veldhuis, Rogier Mous, Christian Bjørn Poulsen, Henrik Frederiksen, Ann Janssens, Ida Schjoedt, Ellen C Dompeling, Juha Ranti, Christian Brieghel, Mattias Mattsson, Mar Bellido, Hoa T Tran, Claudia A M Stege, Kazem Nasserinejad, Arnon P. Kater, Carsten Utoft Niemann, Mark-David Levin
Journal: Blood
Blood (2024) 144 (Supplement 1): 888.
https://doi.org/10.1182/blood-2024-211226
Published: 2024
Journal Articles

Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial

Jennifer R. Brown, John F. Seymour, Wojciech Jurczak, Andrew Aw, Malgorzata Wach, Arpad Illes, Alessandra Tedeschi, Carolyn Owen, Alan P Skarbnik, Daniel Lysak, Ki-Seong Eom, Martin Šimkovič, Miguel Arturo Pavlovsky, Arnon P. Kater, Barbara F. Eichhorst, Kara Miller, Veerendra Munugalavadla, Ting Yu, Marianne de Borja, Paolo Ghia
Journal: Blood
Blood (2024) 144 (Supplement 1): 1009.
https://doi.org/10.1182/blood-2024-200701
Published: 2024
Journal Articles

Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1

Alexey Danilov, Bita Fakhri, Farrukh T. Awan, Hans Herluf Bentzen, Herbert A. Eradat, Carsten Utoft Niemann, Fritz Offner, Christian Bjørn Poulsen, Thor Hoeyer, Mar Bellido, Damien Roos Weil, Alessandra Ferrajoli, Meghan C. Thompson, Jacob Haaber Christensen, Ann Janssens, Tamar Tadmor, Mazyar Shadman, Pegah Jafarinasabian, Jimin Zhang, Marcia Rios, Alexandra Kuznetsova, Rebecca Valentin, Arnon P. Kater
Journal: Blood
Blood (2024) 144 (Supplement 1): 883.
https://doi.org/10.1182/blood-2024-199708
Published: 2024
Journal Articles

Reprogramming CLL T-Cell Mitochondrial Fitness Using PI3K Inhibition for Enhancing CAR T-Cell Therapy

Wael Gamal, Nienke B. Goedhart, Helga Simon-Molas, Melanie Mediavilla Varela, Angimar Uriepero Palma, Fleur S. Peters, Eva Sahakian, Arnon P. Kater, Javier Pinilla-Ibarz
Journal: Blood
Blood (2024) 144 (Supplement 1): 4803.
https://doi.org/10.1182/blood-2024-210992
Published: 2024
Journal Articles

Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial

Moritz Fürstenau, Emelie Curovic Rotbain, Laura Eurelings, Sandra Robrecht, Julia Von Tresckow, Adam Giza, Michael Gregor, Patrick Thornton, Philipp Bernhard Staber, Tamar Tadmor, Vesa Lindström, Gunnar Juliusson, Ann Janssens, Christof Schneider, Thomas Noesslinger, Martin Andres, Adrian Schmidt, Elisabeth Vandenberghe, Lev Shvidel, Christian Bjørn Poulsen, Henrik Frederiksen, Caspar Da Cunha-Bang, Kourosh Lotfi, Rogier Mous, Martine E.D. Chamuleau, Ka Lung Wu, Margriet Oosterveld, Jesus Duque-Afonso, Christian Bogner, Thomas Wolff, Johannes Schetelig, Ursula Vehling-Kaiser, Christoph van Roye, Nadine Kutsch, Anna Maria Fink, Kirsten Fischer, Emily Holmes, Matthias Ritgen, Eugen Tausch, Stephan Stilgenbauer, Michael J. Hallek, Arnon P. Kater, Carsten Utoft Niemann, Mark-David Levin, Barbara F. Eichhorst
Journal: Blood
Blood (2024) 144 (Supplement 1): 3238.
https://doi.org/10.1182/blood-2024-198917
Published: 2024
Journal Articles

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib

Clinical Trials & Observations
Jennifer A. Woyach, Daniel Jones, Wojciech Jurczak, Tadeusz Robak, Árpád Illés, Arnon P. Kater, Paolo Ghia, John C. Byrd, John F. Seymour, Susan Long, Nehad Mohamed, Samon Benrashid, Tzung-Huei Lai, Gary De Jesus, Richard Lai, Gerjan de Bruin, Simon Rule, Veerendra Munugalavadla
Journal: Blood
Blood (2024) 144 (10): 1061–1068.
https://doi.org/10.1182/blood.2023023659
Published: 2024
Includes: Supplemental data
Journal Articles

Impaired T-Cell Proliferation in Chronic Lymphocytic Leukemia Patients Is Linked to Disturbed Lipid Metabolism and Homeostasis

Chaja F. Jacobs, Fleur S. Peters, Gaspard Cretenet, Noam Zelcer, Helga Simon-Molas, Arnon P. Kater
Journal: Blood
Blood (2023) 142 (Supplement 1): 4624.
https://doi.org/10.1182/blood-2023-188520
Published: 2023
Journal Articles

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Othman Al-Sawaf, Moritz Fürstenau, Adam Giza, Sandra Robrecht, Julia Von Tresckow, Anna Maria Fink, Florian Simon, Eugen Tausch, Christof Schneider, Liliya Sivcheva, Anthony Schwarer, Javier Loscertales, Robert Weinkove, Dirk Strumberg, Allanah R. Kilfoyle, Gunnar Juliusson, Caspar Da Cunha-Bang, Thomas Illmer, Michael Gregor, Patrick Thornton, Ann Janssens, Tamar Tadmor, Vesa Lindström, Philipp Bernhard Staber, Mark-David Levin, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Matthias Ritgen, Stephan Stilgenbauer, Arnon P. Kater, Carsten Utoft Niemann, Kirsten Fischer, Barbara F. Eichhorst, Michael Hallek
Journal: Blood
Blood (2023) 142 (Supplement 1): 4639.
https://doi.org/10.1182/blood-2023-188827
Published: 2023
Journal Articles

Response to Subsequent Novel Therapies and Time to Second Progression-Free Survival Event in the MURANO Trial in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with Fixed-Dose Venetoclax Plus Rituximab

Rosemary Anne Harrup, Arnon P. Kater, Barbara F. Eichhorst, Carolyn Owen, Brenda Chyla, Hyun Yong Jin, Yanwen Jiang, Yi Meng Chang, Rosemary Millen, Marcus Lefebure, Maria Thadani-Mulero, Michelle Boyer, John F. Seymour
Journal: Blood
Blood (2023) 142 (Supplement 1): 1898.
https://doi.org/10.1182/blood-2023-177567
Published: 2023
Journal Articles

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Moritz Fürstenau, Matthias Ritgen, Sandra Robrecht, Julia Von Tresckow, Can Zhang, Anke Schilhabel, Michael Gregor, Patrick Thornton, Philipp Bernhard Staber, Tamar Tadmor, Vesa Lindström, Gunnar Juliusson, Ann Janssens, Mark-David Levin, Caspar Da Cunha-Bang, Christof Schneider, Neta Goldschmidt, Elisabeth Vandenberghe, Davide Rossi, Rudolf A. Benz, Daniel Heintel, Christian Bjørn Poulsen, Ilse Christiansen, Henrik Frederiksen, Lisbeth Enggaard, Eduardus Posthuma, Djamila Issa, Hein Visser, Mar Bellido, Nadine Kutsch, Jan Dürig, Alexander Stehle, Matthias C. Voehringer, Sebastian Böttcher, Clemens Schulte, Florian Simon, Anna-Maria Fink, Kirsten Fischer, Emily Holmes, Karl-Anton Kreuzer, Monika Brüggemann, Eugen Tausch, Stephan Stilgenbauer, Michael Hallek, Arnon P. Kater, Carsten Utoft Niemann, Barbara F. Eichhorst
Journal: Blood
Blood (2023) 142 (Supplement 1): 635.
https://doi.org/10.1182/blood-2023-173709
Published: 2023
Journal Articles

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

Carol Moreno, Talha Munir, Carolyn Owen, George Follows, Jose-Angel Hernandez Rivas, Ohad Benjamini, Ann Janssens, Mark-David Levin, Tadeusz Robak, Martin Simkovic, Sergey Voloshin, Vladimir I. Vorobyev, Munci Yagci, Loic Ysebaert, Qianya Qi, Emma Smith, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Donne Bennett Caces, Carsten Utoft Niemann, Arnon P. Kater
Journal: Blood
Blood (2023) 142 (Supplement 1): 634.
https://doi.org/10.1182/blood-2023-177713
Published: 2023
Journal Articles

Evaluation of the T-Cell Metabolic State of Starting Material and Manufactured CAR T Cell Products and Clinical Outcome of CAR T-Cell Therapy for Large B Cell Lymphoma

Chaja F. Jacobs, Helga Simon-Molas, Gaspard Cretenet, Miriam Gutschow, Amy Chattin, Garrett Collett, Lucrezia Colonna, Fleur S. Peters, Arnon P. Kater
Journal: Blood
Blood (2023) 142 (Supplement 1): 3456.
https://doi.org/10.1182/blood-2023-188577
Published: 2023
Journal Articles

Gut Microbiome Links to Disease Stage and Immune Microenvironment in Patients with Chronic Lymphocytic Leukemia

Tereza Faitova, Caspar Da Cunha-Bang, Hans Jakob Hartling, Jakob Thaning Bay, Hanne Vibeke Marquart, Arnon P. Kater, Mark-David Levin, Sabina Kersting, Carsten Utoft Niemann, Rebecka Svanberg
Journal: Blood
Blood (2023) 142 (Supplement 1): 6515.
https://doi.org/10.1182/blood-2023-186158
Published: 2023